An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma

Trial Profile

An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs Reslizumab (Primary)
  • Indications Asthma
  • Focus Adverse reactions
  • Sponsors Teva Branded Pharmaceutical Products R&D
  • Most Recent Events

    • 30 Oct 2017 Planned End Date changed from 5 Sep 2018 to 3 Oct 2018.
    • 30 Oct 2017 Planned primary completion date changed from 31 Aug 2017 to 5 Sep 2018.
    • 30 Oct 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top